Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
globenewswire.com
·

Breast Cancer Clinical Trial Pipeline Appears Robust With

DelveInsight's 'Breast Cancer Pipeline Insight 2024' highlights a robust pipeline with 100+ companies developing 120+ drugs, driven by rising incidence, tech advancements, and increased awareness. Key companies and drugs include Ambrx, CSPC ZhongQi, Merus, and ARX788, DP303c, SHR-A1811, among others. FDA fast-track designations and breakthrough therapy designations for drugs like 9MW2821 and inavolisib underscore significant progress.
nature.com
·

Two decades of advances in clinical oncology — lessons learned and future directions

S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.
liverdiseasenews.com
·

Lanifibranor may promote liver gains seen in Phase 3 MASH trial

Improved liver health biomarkers and reduced scarring observed in MASH patients in lanifibranor Phase 3 trial, similar to Phase 2b NATIVE trial results. NATiV3 trial, enrolling 837 patients, aims to assess MASH resolution and fibrosis reduction at week 72, with interim data showing improved liver function and reduced fibrosis.

Blockchain leaders finesse tech to find fake drugs

Blockchain technology, though effective in tracking drug authenticity, has yet to be fully implemented in the pharma supply chain. Despite challenges like lack of transparency and regulatory obstacles, blockchain can enhance supply chain management, prevent counterfeit drugs, and improve patient outcomes.
hcplive.com
·

Discussing Interim Findings on Nemolizumab for Atopic Dermatitis, with Diamant Thaçi, MD

Nemolizumab therapy showed continuous improvements in atopic dermatitis symptoms up to 56 weeks, with 47% achieving clear or almost clear skin and 73% improving EASI scores by 75%. Nemolizumab, an IL-31 receptor antagonist, demonstrated a favorable safety profile with no unexpected adverse events, positioning it as a valuable long-term treatment option for atopic dermatitis.
pharmaphorum.com
·

BMS ends decades-long drought in novel schizophrenia drugs

Bristol-Myers Squibb's $14 billion acquisition of Karuna Therapeutics pays off with FDA approval for Cobenfy, a novel schizophrenia drug targeting cholinergic receptors. Cobenfy offers a new treatment approach with milder side effects compared to dopamine-blocking drugs, potentially leading to blockbuster sales. BMS plans to launch Cobenfy at $1,850 per month, with further clinical trials underway for additional indications.

Nerandomilast Phase 3 clinical trial meets its primary goal in IPF

Boehringer Ingelheim’s Phase 3 trial of nerandomilast for idiopathic pulmonary fibrosis (IPF) met its primary goal, showing improved lung function or prevention of decline over a year. The trial enrolled 1,177 patients globally, with full data to be presented in 2025. Boehringer plans to seek FDA approval for nerandomilast, which targets phosphodiesterase 4B to reduce inflammation and scarring in IPF and other interstitial lung diseases.
biospace.com
·

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

OSE Immunotherapeutics reports H1 2024 results with €82.5 million income, strategic partnerships with AbbVie and Boehringer Ingelheim, and €80.7 million cash position. Clinical highlights include positive Phase 1/2 results for OSE-279 and Lusvertikimab, and the launch of the Artemia Phase 3 study for Tedopi®.
healio.com
·

Tulisokibart bests placebo, may yield 'important clinical benefit' via TL1A blockade in UC

Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to the ARTEMIS-UC trial. The study incorporated a predictive biomarker for response, showing significant clinical remission, endoscopic improvement, and clinical response in patients on tulisokibart compared to placebo. A phase 3 program is planned to confirm these results.
quantisnow.com
·

Avantor® Joins Pharmaceutical Industry-Sponsored Energize Virtual Power Purchase Agreement

Avantor enters 10-year virtual power purchase agreement for 25GWh of renewable energy annually from 2026, supporting three new solar projects in Spain. The agreement reflects Avantor's commitment to reducing greenhouse gas emissions and lowering supply chain costs.
© Copyright 2024. All Rights Reserved by MedPath